Literature DB >> 8465513

Immunohistochemical detection of the p53 oncoprotein in tumours of melanocytic origin.

M Yamamoto1, H Takahashi.   

Abstract

We employed the polyclonal anti-p53 antibody NCL-CM1 to cultured cells and pathological tissues in order to investigate the expression of p53 oncoprotein in human malignant melanomas. The results in the cultured cells showed that the antigenic determinant was sensitive to formalin fixation, resulting in a lower reactivity than with fixation by alcohol. In pathological tissues, the expression of p53 oncoprotein increased with progression of the tumour. Among 79 melanomas 37 (47%) showed distinct nuclear labelling and the highest proportion of reactive cells was observed in metastatic melanomas (mean 4.8%). An immunocytochemical study also revealed the presence of mutant-type oncoprotein in human melanoma cell lines, which was recognized by monoclonal antibody P240, and we confirmed that the molecular weight of the antigens recognized by both antibodies was 53 kDa by Western blot analysis. Therefore, although the presence of point mutations in human melanomas is yet to be confirmed our data suggest that the antigen detected by NCL-CM1 is a mutant-type or a complex of mutant and wild-type p53 oncoproteins. This antibody may be useful in retrospective studies of tumours of melanocytic origin.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8465513     DOI: 10.1007/bf01607164

Source DB:  PubMed          Journal:  Virchows Arch A Pathol Anat Histopathol        ISSN: 0174-7398


  33 in total

1.  Expression of p53 protein in cutaneous melanoma.

Authors:  L A Akslen; O Mørkve
Journal:  Int J Cancer       Date:  1992-08-19       Impact factor: 7.396

2.  Cancer genes. Telling changes of base.

Authors:  A L Harris
Journal:  Nature       Date:  1991-04-04       Impact factor: 49.962

3.  T antigen is bound to a host protein in SV40-transformed cells.

Authors:  D P Lane; L V Crawford
Journal:  Nature       Date:  1979-03-15       Impact factor: 49.962

Review 4.  Oncogenes and anti-oncogenes; the molecular basis of tumour behaviour.

Authors:  D Wynford-Thomas
Journal:  J Pathol       Date:  1991-11       Impact factor: 7.996

5.  Analysis of the antigenic profile of uveal melanoma lesions with anti-cutaneous melanoma-associated antigen and anti-HLA monoclonal antibodies.

Authors:  P G Natali; A Bigotti; M R Nicotra; R M Nardi; A Delovu; O Segatto; S Ferrone
Journal:  Cancer Res       Date:  1989-03-01       Impact factor: 12.701

6.  P53 protein expression in lymphomas and reactive lymphoid tissue.

Authors:  R Villuendas; M A Piris; J L Orradre; M Mollejo; P Algara; L Sanchez; J C Martinez; P Martinez
Journal:  J Pathol       Date:  1992-03       Impact factor: 7.996

7.  Heterogeneity of the response to inducers of differentiation and to cytostatics of tumor cell populations.

Authors:  I Pályi
Journal:  Pathol Res Pract       Date:  1988-12       Impact factor: 3.250

8.  Mutations of the p53 gene in human myeloma cell lines.

Authors:  G R Mazars; M Portier; X G Zhang; M Jourdan; R Bataille; C Theillet; B Klein
Journal:  Oncogene       Date:  1992-05       Impact factor: 9.867

9.  Cross-sensitivity of methylating agents, hydroxyurea, and methotrexate in human tumor cells of the Mer- phenotype.

Authors:  K Maynard; P G Parsons
Journal:  Cancer Res       Date:  1986-10       Impact factor: 12.701

10.  Increased expression of mutant forms of p53 oncogene in primary lung cancer.

Authors:  R Iggo; K Gatter; J Bartek; D Lane; A L Harris
Journal:  Lancet       Date:  1990-03-24       Impact factor: 79.321

View more
  2 in total

1.  [Isolation of mitochondrial DNA binding proteins which are specific for maize cox1 promoter].

Authors:  V I Tarasenko; I Iu Subota; V F Kobzev; Iu M Konstantinov
Journal:  Mol Biol (Mosk)       Date:  2005 May-Jun

2.  Expression of the p53 protein in malignant melanomas as a prognostic indicator.

Authors:  M Yamamoto; H Takahashi; K Saitoh; T Horikoshi; M Takahashi
Journal:  Arch Dermatol Res       Date:  1995       Impact factor: 3.017

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.